Format

Send to

Choose Destination
Pac Asia Inq. 2015 Fall;6(1):144-150.

Developing a Betel Quid Cessation Program on the Island of Guam.

Author information

1
University of Guam UOG Station Mangilao, GU 96923.
2
University of Hawaii Cancer Center 701 Ilalo Street Honolulu, HI 96813.
3
School of Nursing and Health Sciences University of Guam UOG Station Mangilao, GU 96923.

Abstract

Betel quid is a psychoactive drug preparation typically made up of a combination of areca quid, slaked lime, piper betel leaf and tobacco. It is the fourth most commonly consumed drug in the world with global use concentrated in the Asia-Pacific region (Boucher and Mannan, 2002; Warnakulasuriya and Peters, 2002). The International Agency for Research on Cancer has classified betel quid as a Group 1 carcinogen (IARC, 2004; Lin et al., 2006), and its use has been associated with oral and oropharyngeal cancer, oral lesions, oral leukoplakia, submucous fibrosis, gum disease, and cancer of the pharynx and esophagus (IARC, 2004; Oakley et al., 2005; Shah et al., 2002; Warnakulasuriya, 2002). This paper reports on the feasibility of an innovative betel quid cessation program carried on the U.S. territory of Guam, and is the first of its kind. The program is described, along with the challenges encountered during the implementation process.

PMID:
27057560
PMCID:
PMC4821189

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center